The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
about
Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRILUpdate on therapeutic options in Waldenström macroglobulinemiaInhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cellsAberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survivalCommon variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma riskDeregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitorsGenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells.A library of gene expression signatures to illuminate normal and pathological lymphoid biology.A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments.APRIL is overexpressed in cancer: link with tumor progressionPhase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.Oncogenic activation of NF-kappaB.Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells.Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation.Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-GenomicsWaldenstrom macroglobulinemiaAntibody-based therapies in multiple myelomaSignaling by the tumor necrosis factor receptor superfamily in B-cell biology and diseaseDifferential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.Enhancement of clonogenicity of human multiple myeloma by dendritic cellsBone marrow microenvironment and the identification of new targets for myeloma therapy.The expression of APRIL in Sjogren's syndrome: aberrant expression of APRIL in the salivary gland.Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myelomaAn APRIL to remember: novel TNF ligands as therapeutic targets.Microarray-based understanding of normal and malignant plasma cells.Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia.Signaling pathways for B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in human placenta.The molecular characterization and clinical management of multiple myeloma in the post-genome era.APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
P2860
Q24681342-3AD6509F-5E83-49B2-97B7-3E7D7EABCD35Q28304195-2DE1B16B-1C1F-4F42-9311-7778DCBED091Q28487347-810B2076-DDEF-456A-8D6F-38019F957FC1Q28743862-9850B412-0904-49C9-A3BA-94D5D349BD0AQ28943335-5DA30305-9138-41AD-B217-488B6F784812Q30436741-93ED0D6E-6397-4884-A42E-E35FA0AF98C9Q30886634-73BD6BB7-3AB7-4E94-81E7-1370A343144DQ33240316-227C579A-C248-470D-9217-165201C3E86BQ33314438-A3D2A205-99E9-4583-B49F-82CCDF6BBDD2Q33418752-46628DE7-A489-4996-8BF0-376AB0F30DFEQ33437811-9793401F-A960-4FD0-BE64-E4E1221CA84FQ33564854-C3EDE419-CB24-4971-94B3-71AE2FCB80F2Q33577408-34952F43-B9FE-4825-ABCA-C9A06BDE0E6BQ33621610-7E8B8118-8651-4767-B271-B5DC38DEE56DQ33748979-C9E7A696-55D2-4366-A924-A1F988388685Q33849388-D6398B48-0A78-403F-BBDF-357A5B1B8150Q33889168-8A6A55D8-27F3-4A2D-A76F-52F6142D52FAQ34022979-85371AC3-E503-44A2-98B7-8404D4D2F93FQ34104277-F5090CE2-297E-4618-9B50-C5732C7E9844Q34155848-18C82CA1-45BC-4542-B1E9-E4BA9B8B234FQ34159016-EEF8F592-DD50-4FC8-B204-73AF7840BE7BQ34364560-220C340E-DE7E-4C85-AD30-19D4F874CAC1Q34451553-D5D130B3-2948-4E53-9C85-783FA92D5428Q35051171-D46B8181-033C-4AC1-95EE-9E1A0E52981BQ35097328-18FD62EA-1C0D-4354-B208-CCCFFC527BE7Q35431150-274DC521-0B79-4D34-A967-C7626089C1E4Q35452032-C1AAC443-78E2-40DF-B2E2-72109B9FCECDQ35630042-E83E0566-B3D8-4869-9EE2-6DA3C9FC2958Q35989478-66628F26-0A01-4CDB-BF65-772B9CD88D06Q36082990-B8664FEE-4C98-4287-88C4-C7185A50936AQ36162703-209201C4-3B73-44FE-A6A6-63E3E1FAA0C6Q36162832-4A68C192-1301-4CF8-AD0E-593B8E2755A7Q36206430-B9899FC3-9FDD-4FC1-BA35-726ECFA46DA9Q36394955-30E5DE50-6232-4F53-B91C-7E2A26D0270BQ36453354-53359E67-EDA2-4659-B42B-56BD99E47045Q36499443-2F5848EC-CE25-4DFD-A2A5-322AB3049E37Q36530420-AFAD8A94-3ED5-43A7-B772-CAE2D503EA94Q36579827-27DC16FE-DA6D-450E-B451-A32C04B61BE0Q36939043-5E2B5630-B0D6-48C0-8CDF-E967B8621C9DQ37035836-C13C309F-6C4B-4978-B894-8FECB2CBEB6F
P2860
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The level of TACI gene express ...... rsus a plasmablastic signature
@ast
The level of TACI gene express ...... rsus a plasmablastic signature
@en
The level of TACI gene express ...... rsus a plasmablastic signature
@nl
type
label
The level of TACI gene express ...... rsus a plasmablastic signature
@ast
The level of TACI gene express ...... rsus a plasmablastic signature
@en
The level of TACI gene express ...... rsus a plasmablastic signature
@nl
prefLabel
The level of TACI gene express ...... rsus a plasmablastic signature
@ast
The level of TACI gene express ...... rsus a plasmablastic signature
@en
The level of TACI gene express ...... rsus a plasmablastic signature
@nl
P2093
P2860
P50
P1433
P1476
The level of TACI gene express ...... rsus a plasmablastic signature
@en
P2093
Anna Jauch
Bernard Klein
Eric Jourdan
Eric Legouffe
Friedrich W Cremer
Genevieve Fiol
Jean François Rossi
Karene Mahtouk
P2860
P304
P356
10.1182/BLOOD-2004-11-4512
P407
P577
2005-04-12T00:00:00Z